Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
ADC Online First, published on February 20, 2015 as 10.1136/archdischild-2014-307089 Review
Recent advances in paediatric gastroenterology Richard Hansen,1 Richard K Russell,1 Rafeeq Muhammed2 1
Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Sick Children, Glasgow, UK 2 Department of Paediatric Gastroenterology and Nutrition, Birmingham Children’s Hospital, Birmingham, UK Correspondence to Dr Rafeeq Muhammed, Department of Paediatric Gastroenterology and Nutrition, Birmingham Children’s Hospital NHS Foundation Trust, Birmingham B4 6NH, UK; [email protected] Received 30 November 2014 Revised 21 January 2015 Accepted 28 January 2015
ABSTRACT Over the last few years, many changes have been introduced in the diagnosis and management of paediatric gastrointestinal problems. This review highlights the recent developments in Helicobacter pylori infection, eosinophilic oesophagitis, coeliac disease and inflammatory bowel disease.
INTRODUCTION Over the last few years, many changes have been introduced in the diagnosis and management of paediatric gastrointestinal problems. This review highlights the recent developments in Helicobacter pylori infection, eosinophilic oesophagitis (EO), coeliac disease and inflammatory bowel disease (IBD).
H. PYLORI INFECTION
To cite: Hansen R, Russell RK, Muhammed R. Arch Dis Child Published Online First: [ please include Day Month Year] doi:10.1136/archdischild2014-307089
There is a quiet pathophysiology revolution going on in the upper gastrointestinal tract that might have consequences for human health more broadly. The natural state of the human stomach is colonisation with H. pylori, with genetic evidence showing how closely linked the evolution of our two species is.1 In the majority of H. pylori-infected stomachs, the organism acts to reduce gastric acidity through production of urease. In recent years, H. pylori has generally been eradicated whenever found with little thought to the consequences. H. pylori carriage appears to be negatively associated with conditions as broad as allergy, asthma, obesity and acid reflux, all conditions on the rise, suggesting that the health consequences of population-level eradication of H. pylori may be significant.1 Current consensus guidelines on H. pylori in childhood are ambiguous about eradication of the organism when identified incidentally; however, eradication is supported by UK paediatric gastroenterologists when the organism is found, including in an otherwise normal-appearing stomach.2 3 The diagnosis and management of H. pylori in children are well described in the joint consensus guideline of European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and North American Society of Paediatric Gastroenterology, Hepatology and Nutrition (summarised in box 1),3 with diagnosis having been summarised recently for Archives sister journal.4 Further discussion on H. pylori diagnosis and management therefore is out with the scope of this review. The emergence of a ‘new’ clinical atopic disease in the oesophagus, EO, around 20 years ago has not yet been fully explained.5 Data are however emerging supporting a negative association between H. pylori and EO, including in children.6 7 One challenge of linking other conditions to H. pylori is the confounder of the hygiene hypothesis as atopic
conditions have long been linked to increasing societal cleanliness, with H. pylori infection being increased in the opposite circumstance. The impact of a continued reduction in H. pylori prevalence on the health of children warrants significant consideration, particularly in the aetiological study of emerging diseases or those with changing incidence. It is unlikely however that the current decline in H. pylori prevalence can now be halted, and since there is unlikely to be uptake for deliberate inoculation of healthy people with a known carcinogen, there is likely little that can be done to address the unintended pathophysiological sequelae of H. pylori eradication.
EOSINOPHILIC OESOPHAGITIS EO is a primary oesophageal disorder characterised by an eosinophilic inflammatory infiltrate, driven by airborne or food-based allergens and resulting in oesophageal dysfunction. Symptoms vary with age of presentation, becoming more localised and specific with age.8 9 Younger children often present with vague symptoms such as feeding disorders, vomiting and abdominal pain, while the more specific symptoms of dysphagia and food impaction are more associated with teenage patients.8 The natural history is not fully understood but may lead to oesophageal stricture in untreated patients (figure 1). Affected patients are often atopic, particularly to foods, with an unexplained almost 3/4 male preponderance.10 11 Diagnosis of EO relies on oesophageal biopsy in children symptomatic of oesophageal dysfunction and so vigilance is required in identifying appropriate patients for endoscopic investigation, particularly in general or atopic paediatric practice (box 2). Confirmation of >15 eosinophils per highpowered field is the current standard diagnostic criterion.12 The oesophagus may look normal on endoscopy and, although there are no pathognomic features, some characteristic findings may be seen macroscopically such as trachealisation. Recent recommendations support taking 2–4 biopsies from the upper and lower oesophagus with important caveats being that gastroesophageal reflux disease is the main differential diagnosis, and endoscopic oesophageal pinch biopsies sample only the superficial mucosa.12 Initial confusion surrounding eosinophilic infiltration in gastroesophageal reflux disease and the early dogma that EO was non-responsive to acidsuppressant therapy have since been addressed with the recognition that a subset of patients with apparent EO are responsive to proton pump inhibitors (PPI).12 13 This is pragmatically an important point for the general paediatrician, with symptoms unresponsive to PPI acting as a good marker for tertiary gastroenterology referral (box 2). The concept of
Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
1
Copyright Article author (or their employer) 2015. Produced by BMJ Publishing Group Ltd (& RCPCH) under licence.
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Review Box 1 The diagnosis and management of Helicobacter pylori based on the European Society of Paediatric Gastroenterology, Hepatology and Nutrition/the North American Society of Paediatric Gastroenterology, Hepatology and Nutrition Guidelines (2011)3 Initial diagnosis ▸ Symptomatic children should be tested with the aim of diagnosing the cause of symptoms rather than simply identifying H. pylori. ▸ Testing those with a family history of gastric cancer or idiopathic iron deficiency anaemia should be considered. ▸ Testing in functional abdominal pain is not recommended. ▸ Upper gastrointestinal endoscopy with biopsy for histology/ rapid urease test is the recommended gold-standard for its ability to correlate carriage with associated pathology. ▸ Blood-based serology tests are not reliable for use in routine clinical practice in children. ▸ Non-invasive tests, for example, stool antigen testing, should be reserved for confirmation of eradication. Management ▸ First-line eradication regimens include triple therapy with omeprazole, amoxicillin, metronidazole; omeprazole, amoxicillin and clarithromycin; bismuth salts, amoxicillin and metronidazole or sequential therapy. ▸ Triple therapy duration should be 7–14 days. (As eradication rates are highest during the first treatment course and increased by up to 5% in 14-day courses, 14 days is the favoured option of the authors.)38 Confirmation of eradication ▸ Eradication of H. pylori should be confirmed 4–8 weeks after treatment. ▸ Patients should be off acid suppression for at least two weeks and antibiotics for at least four weeks before testing. ▸ Confirmation of eradication should be based on faecal antigen testing or urease breath test, with the former becoming the standard of practice because of ease of testing.
PPI responsiveness has since been incorporated into ESPGHAN consensus guidelines with the, perhaps confusing but pragmatic, description of PPI-responsive oesophageal eosinophilia (PPI-ROE).12 It remains unclear whether PPI-ROE and EO are distinct entities; nevertheless, the first step in the management of EO within the recent guidelines is to test for PPI responsiveness, presumably as this then becomes the mainstay therapy for this group of (∼4/10) patients. Confirmation of response should be histological, with one of the major challenges of caring for EO children being a reliance on endoscopy for objective
evaluation of disease progression, although change in symptoms can be a useful proxy in some patients. No surrogate biomarker of oesophageal eosinophilic infiltration is in current routine practice. For children not responsive to PPI treatment, there are two competing options, each with similar efficacy, namely dietary restriction and use of topical steroids. Taking these in turn, dietary therapy is most effective when a restrictive elemental diet is used (96% remission), though this is socially inconvenient and difficult to maintain in the medium to long term.14 Efficacy is reduced but similarly high (81% remission) with a six-food elimination diet excluding milk, egg, soya, wheat, nuts ( peanuts and tree nuts) and fish (including shellfish).14 About a third of children will respond to a single food exclusion, and remission rates of 77% can be achieved by milk exclusion in addition to targeted exclusion based on positive skin-prick and allergen patch testing, though the sensitivity/specificity of tests vary considerably with different foods.15 There is currently no randomised controlled trial (RCT) evidence supporting nutritional therapy in EO. Steroid intervention is however supported by specific paediatric RCTs with both fluticasone and budesonide having proven efficacy against placebo when swallowed.16 17 ‘Asthma-type’ steroids are used in order to take advantage of topical effect in the oesophagus but high first-pass metabolism and a subsequent reduction in systemic side effects. Swallowed asthma-type steroids that are extensively metabolised by first–pass metabolism (eg, beclomethasone, fluticasone) are particularly useful where aeroallergens are implicated in the development of EO. The current EO guidelines do not advocate dietary therapy over topical steroids or vice versa, but present a choice after failed response to PPI treatment.12 Systemic steroids are not recommended out with severe dysphagia, dehydration, weight loss, oesophageal strictures and failure of other treatments. Although it is recognised that stricturing can occur in EO, the natural history of this complication has not been fully described, hence the desired outcome in EO management at present remains histological remission, which is not always linked to clinical response. Again, a dependence on endoscopic reassessment is currently required in these children, at least until an adequate non-invasive surrogate marker is widely available. For the general paediatrician, an awareness of EO and its clinical manifestation and investigation will help in identifying such patients from within cohorts of other atopic disease. The requirement for endoscopy will mean paediatric gastroenterologists are likely to manage the majority of these patients in the long term at present.
COELIAC DISEASE Coeliac disease continues to remain as a major childhood healthcare problem in the UK. A recent report from Scotland showed that the incidence of coeliac disease has increased from 1.8 to 11.7/100 000 between the period of 1990 to 1994 and 2005 to 2009, respectively.18 This paper showed an actual increase in the number of children presenting with classic
Figure 1 Natural history of eosinophilic oesophagitis symptoms in childhood.
2
Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Review Box 2 When to suspect eosinophilic oesophagitis Children 10 years Dysphagia or odynophagia symptoms, particularly if gradual onset. Food bolus obstruction in the oesophagus. All children Chronic vomiting or food regurgitation. Non-specific chest or abdominal pain in atopic child. Unexplained weight loss/food avoidance, particularly in atopic child. Gastroesophageal reflux symptoms unresponsive to proton pump inhibitors therapy.
symptoms of coeliac disease and also the children diagnosed with coeliac disease by active screening. The increased incidence of coeliac disease over the last three decades has been reported in South Wales as well.19 In this Welsh study, it was noted that >50% of patients exhibited few or no symptoms of coeliac disease and that the median age of diagnosis of coeliac disease had increased. The British Society of Paediatric Gastroenterology, Hepatology and Nutrition and ESPGHAN have published guidelines recently on the diagnosis of coeliac disease in children.20 21 These guidelines allow the diagnosis of coeliac disease in symptomatic children without endoscopy and duodenal biopsy if they have significantly elevated coeliac antibody titres (ie, tissue transglutaminase >10 times upper limit of normal) on two occasions and high-risk human leucocyte antigen (HLA) genotype (HLA DR3-DQ2 or DR4-DQ8). This diagnostic approach without endoscopy and biopsy contrasts with the recently published guideline for diagnosis of coeliac disease in adults, where the recommendation is for biopsy confirmation of coeliac disease.22 It is important to highlight that children should not be started on gluten-free diet for coeliac disease without the diagnosis being confirmed by a paediatric gastroenterologist or paediatrician with gastroenterology interest. Genetics and dietary exposure of gluten are important factors in the development of coeliac disease. HLA DR3-DQ2 and DR4-DQ8 are the strongest susceptibility loci in the development of coeliac disease. However, not everyone with these HLA genotypes develop coeliac disease. The chance of developing coeliac disease in children with genetic risk depends on the gene dose effect.23 A total of 6403 children with HLA haplotype DR3-DQ2 or DR4-DQ8 were followed up prospectively from birth. The risks of coeliac disease-associated antibody positivity and coeliac disease by the age of 5 years were 11% and 3%, respectively, among children with a single DR3-DQ2 haplotype and 26% and 11%, respectively, among those with two copies (DR3-DQ2 homozygosity). These results show that the DR3-DQ2 haplotype has a gene dose effect. Strict and lifelong gluten-free diet is the treatment of coeliac disease. Gluten-free diet normalises the small bowel mucosal changes and also reduces the symptoms of coeliac disease. Gluten-free diet is also recommended for asymptomatic patients with coeliac disease. Many asymptomatic patients challenge this advice based on the practical difficulties of adhering to a restricted diet when they cannot perceive the symptomatic Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
improvement. Recent reports from Finland showed that gastrointestinal symptoms, coeliac disease-associated antibodies and mucosal changes improved in asymptomatic adults with coeliac serology positivity when randomised to gluten-free diet compared with the group randomised to gluten-containing diet.24 Only social function scores improved more in the glutencontaining diet group than in the gluten-free diet group. No study subjects considered their experience to be negative and most expected to remain on gluten-free diet. Research is progressing in the field of non-dietary treatment of coeliac disease. Recently, recombinant gluten-specific proteases have been found to be effective in adult patients with coeliac disease.25 ALV003 contains a prolyl endopeptidase from Sphingomonas capsulate in combination with another endopeptidase from germinating barley. Adults with biopsy-proven coeliac disease were randomised to receive ALV003 or placebo drug along with daily gluten challenge. Gastrointestinal symptoms secondary to gluten ingestion and mucosal injury were greater in the placebo group. There are currently no effective strategies for the prevention of coeliac disease. The Norwegian Mother and Child Cohort Study found an increased risk of coeliac disease in children introduced to gluten after 6 months.26 However, this finding is not replicated in the recently published research by Italian Society of Pediatric Gastroenterology Hepatology and Nutrition, which showed that neither breast feeding nor delayed introduction of gluten prevented the development of coeliac disease among infants at high risk.27 A total of 832 newborn infants who had a first-degree relative with coeliac disease were randomised to introduction of gluten at 6 or 12 months. The study subjects were screened for coeliac disease by serology testing at regular intervals. Even though at 2 years of age coeliac disease incidence was lower in children with delayed gluten introduction, at 5 years of age, coeliac serology positivity or overt coeliac disease was not significantly different between the two groups. A high-risk HLA genotype (HLA DR3-DQ2 or DR4-DQ8) was the most important factor in the development of coeliac disease (box 3).
INFLAMMATORY BOWEL DISEASE The diagnosis of IBD has become more commonplace during paediatric years.28 Recent studies have particularly noted a rapid rise in the number of children diagnosed with Crohn’s disease making an up-to-date knowledge of the presentation together with the initial investigation and management all the more important. Although the median age at which children are diagnosed with IBD has dropped slightly, clearly the presenting features and examination findings of IBD have not (table 1). Particular attention on examination should be paid to perioral and perianal inspection in children suspected of having Crohn’s disease, as well as measurement and plotting of growth parameters in all children. In children suspected to have IBD, after exclusion of enteric infection (including Clostridium difficile), a panel of simple blood tests (full blood count, erythrocyte sedimentation rate, C-reactive protein, liver function test) will show at least one abnormality in around 80% of children.29 In children where the diagnosis still remains uncertain, the measurement of a faecal inflammatory marker (most commonly faecal calprotectin (FC)) is helpful. Confirmation of a diagnosis of suspected IBD should then be made by a specialist in paediatric gastroenterology using upper and lower gastrointestinal endoscopy with biopsy together with small bowel imaging.30 Recently, the traditional examination of a barium follow-through to assess the small 3
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Review Box 3 Recent advances in coeliac disease
Box 4 Diagnostic use of faecal calprotectin
▸ Coeliac disease can be diagnosed in a selected group of symptomatic children without the need for endoscopy and biopsy ▸ Human leucocyte antigen DR3-DQ2 and DR4-DQ8 are the strongest susceptibility loci in the development of coeliac disease. ▸ Strict and lifelong gluten-free diet is the recommended treatment for both symptomatic and asymptomatic patients with coeliac disease. ▸ Research is progressing in the field of non-dietary treatment of coeliac disease. ▸ There are no effective preventive strategies for coeliac disease.
▸ Faecal calprotectin complements clinical review of patients with gastrointestinal symptoms and should not be used in isolation but in parallel with the clinical picture ▸ Minor elevation of faecal calprotectin above the normal range (usually reported as 250 mg/g. ▸ In healthy preschool children, faecal calprotectin is above the normal adult range. Referral for further gastrointestinal investigations or opinion should be based predominantly on symptoms as faecal calprotectin is not usually helpful in this age group. ▸ Faecal calprotectin is significantly raised at inflammatory bowel disease diagnosis in the vast majority of children, even in the presence of normal blood tests. ▸ Other conditions causing significant elevation of faecal calprotectin include enteric infection and juvenile polyps.
bowel has been replaced by small bowel MRI imaging, usually enterography.
ROLE OF FC IN THE DIAGNOSIS OF IBD FC is a neutrophil marker that can be easily and relatively inexpensively measured in serum and stool. Its great clinical utility is being able to differentiate between non-infectious diarrhoea and IBD (box 4). Studies have clearly demonstrated that the median value at paediatric IBD diagnosis is higher than that of healthy paediatric controls who have been shown conclusively not to have IBD by endoscopy and biopsy.31 In this study, a median value of 1265 mg/g was found in treatment naïve patients with IBD at diagnosis compared with controls who had a value of 65 mg/g. The exact value that signifies when a patient should have further investigation for IBD is not universally agreed, but in working practice the authors would use a value of >250 mg/g to signify the need for follow-up or further investigations.32 The reported normal range of FC is 160 genes implicated in IBD pathogenesis.33 There is no major difference between the genetics of IBD in children and adults despite the fact that children have a more extensive disease phenotype. This similarity excludes patients with very early onset disease under age 6 and especially under age 2 who have often been found to have a monogenic cause for their IBD rather than the polygenic disease of older children and adults.34 These scientific advances have not been widely translated into clinical practice in contrast to targeted pharmacogenomic studies that look to represent an area of exciting clinical application of these recent genetic advances.35 The genetic work has been paralleled and perhaps overtaken by studies examining changes in the microbiome prior to and during IBD disease course. Indeed, the largest genetic IBD study undertaken to date in IBD has placed genetic response to the gut microbiome at the core of IBD pathogenesis.36 The altered gut microbiome at IBD diagnosis with an imbalance of the microbiota compared with healthy controls is generally described by the term ‘dysbiosis’.37 Crohn’s disease is likely to result from a reduced bacterial diversity within the gut microbiome but an increase in the total number of bacteria compared with healthy controls. Scientific evidence exists for specific species in the aetiology of these changes, for example, pathogenic strains of Escherichia coli, but in truth the key species driving these changes vary between study populations and Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Review methodologies so the search for the ‘gatekeeper’ continues. There are active research programmes looking at how these bacterial populations can be changed clinically using, for example, exclusive enteral nutrition in Crohn’s disease and faecal transplantation in ulcerative colitis. Microbial therapeutics looks likely to become the next revolution in IBD therapy. The management of IBD has been extensively updated recently with several joint publications from ESPGHAN and European Crohn’s and Colitis Organisation in the past few years and hence not covered in this review. Acknowledgements The Yorkhill IBD team is generously supported by the Catherine McEwan Foundation and the Yorkhill IBD fund. RKR is supported by an NHS Research Scotland career fellowship award and MRC extension grant for PICTS (G0800675). Contributors All the authors have contributed equally to the manuscript drafting, review and revision. All authors approved the final manuscript as submitted. Competing interests RH has received speaker’s fees and/or travel support from MSD Immunology, Dr Falk and SHS Nutricia. RKR has received speaker’s fees, travel support and/or participated in medical board meetings with MSD Immunology, Abbvie, Dr Falk, Nestle, Janssen, Takeda and Napp. RM has received speaker’s fees, educational support and research grants from Abbvie, Dr Falk, MSD Immunology, Nestle and Tilotts Pharma. Provenance and peer review Commissioned; externally peer reviewed.
15
16
17
18 19 20
21
22
23 24
25
REFERENCES 1 2 3
4 5 6 7
8
9 10 11
12 13
14
Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009;119:2475–87. Goddard M, Lloyd C, Beattie RM, et al. Paediatric Helicobacter pylori practice in the United Kingdom: a BSPGHAN survey. J Pediatr Gastroenterol Nutr 2012;55:339. Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011;53:230–43. Crowley E, Bourke B, Hussey S. How to use Helicobacter pylori testing in paediatric practice. Arch Dis Child Educ Pract Ed 2013;98:18–25. Attwood SE, Smyrk TC, DeMeester TR, et al. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 1993;38:109–16. Elitsur Y, Alrazzak BA, Preston D, et al. Does Helicobacter pylori protect against eosinophilic esophagitis in children? Helicobacter 2014;19:367–71. Dellon ES, Peery AF, Shaheen NJ, et al. Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology 2011;141:1586–92. Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009;48:30–6. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004;351:940–1. van Rhijn BD, Verheij J, Smout AJ, et al. Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. Neurogastroenterol Motil 2013;25:47–52. Dalby K, Nielsen RG, Kruse-Andersen S, et al. Eosinophilic oesophagitis in infants and children in the region of southern Denmark: a prospective study of prevalence and clinical presentation. J Pediatr Gastroenterol Nutr 2010;51:280–2. Papadopoulou A, Koletzko S, Heuschkel R, et al. Management guidelines of eosinophilic esophagitis in childhood. J Pediatr Gastroenterol Nutr 2014;58:107–18. Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 2009;154:96–100. Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2012;129:1570–8.
Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
26 27 28 29
30
31
32
33 34 35
36 37
38
Spergel JM, Brown-Whitehorn TF, Cianferoni A, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol 2012;130:461–7. Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139:418–29. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:1381–91. White LE, Merrick VM, Bannerman E, et al. The rising incidence of celiac disease in Scotland. Pediatrics 2013;132:e924–31. Whyte LA, Jenkins HR. The epidemiology of coeliac disease in South Wales: a 28-year perspective. Arch Dis Child 2013;98:405–7. Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease. J Pediatr Gastroenterol Nutr 2012;54:136–60. Murch S, Jenkins H, Auth M, et al. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children. Arch Dis Child 2013;98:806–11. Ludvigsson JF, Bai JC, Biagi F, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut 2014;63:1210–28. Liu E, Lee HS, Aronsson CA, et al. Risk of pediatric celiac disease according to HLA haplotype and country. N Engl J Med 2014;371:42–9. Kurppa K, Paavola A, Collin P, et al. Benefits of a gluten-free diet for asymptomatic patients with serologic markers of celiac disease. Gastroenterology 2014;147:610–17. Lahdeaho ML, Kaukinen K, Laurila K, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 2014;146:1649–58. Stordal K, White RA, Eggesbo M. Early feeding and risk of Celiac disease in a prospective birth cohort. Pediatrics 2013;132:e1202–9. Lionetti E, Castellaneta S, Francavilla R, et al. Introduction of gluten, HLA status, and the risk of celiac disease in children. N Engl J Med 2014;371:1295–303. Henderson P, Hansen R, Cameron FL, et al. The rising incidence of paediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis 2012;18:999–1005. Quail MA, Russell RK, Van Limbergen JE, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis 2009;15:756–9. Levine A, Koletzko S, Turner D, et al. The ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents. J Pediatr Gastroenterol Nutr 2013;58:795–806. Henderson P, Casey A, Lawrence SJ, et al. The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease. Am J Gastroenterol 2012;107:941–9. Henderson P, Anderson NH, Wilson DC. The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2014;109:637–45. Van LJ, Radford-Smith G, Satsangi J. Advances in IBD genetics. Nat Rev Gastroentero Hepatol 2014;11:372–85. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut 2013;62:1795–805. Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014;46:1131–4. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119–24. Hold GL, Smith M, Grange C, et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 2014;20:1192–210. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646–64.
5
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Recent advances in paediatric gastroenterology Richard Hansen, Richard K Russell and Rafeeq Muhammed Arch Dis Child published online February 20, 2015
Updated information and services can be found at: http://adc.bmj.com/content/early/2015/02/20/archdischild-2014-30708 9
These include:
References
This article cites 38 articles, 8 of which you can access for free at: http://adc.bmj.com/content/early/2015/02/20/archdischild-2014-30708 9#BIBL
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.
Topic Collections
Articles on similar topics can be found in the following collections Metabolic disorders (673)
Notes
To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions To order reprints go to: http://journals.bmj.com/cgi/reprintform To subscribe to BMJ go to: http://group.bmj.com/subscribe/
ADC Online First, published on February 20, 2015 as 10.1136/archdischild-2014-307089 Review
Recent advances in paediatric gastroenterology Richard Hansen,1 Richard K Russell,1 Rafeeq Muhammed2 1
Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Sick Children, Glasgow, UK 2 Department of Paediatric Gastroenterology and Nutrition, Birmingham Children’s Hospital, Birmingham, UK Correspondence to Dr Rafeeq Muhammed, Department of Paediatric Gastroenterology and Nutrition, Birmingham Children’s Hospital NHS Foundation Trust, Birmingham B4 6NH, UK; [email protected] Received 30 November 2014 Revised 21 January 2015 Accepted 28 January 2015
ABSTRACT Over the last few years, many changes have been introduced in the diagnosis and management of paediatric gastrointestinal problems. This review highlights the recent developments in Helicobacter pylori infection, eosinophilic oesophagitis, coeliac disease and inflammatory bowel disease.
INTRODUCTION Over the last few years, many changes have been introduced in the diagnosis and management of paediatric gastrointestinal problems. This review highlights the recent developments in Helicobacter pylori infection, eosinophilic oesophagitis (EO), coeliac disease and inflammatory bowel disease (IBD).
H. PYLORI INFECTION
To cite: Hansen R, Russell RK, Muhammed R. Arch Dis Child Published Online First: [ please include Day Month Year] doi:10.1136/archdischild2014-307089
There is a quiet pathophysiology revolution going on in the upper gastrointestinal tract that might have consequences for human health more broadly. The natural state of the human stomach is colonisation with H. pylori, with genetic evidence showing how closely linked the evolution of our two species is.1 In the majority of H. pylori-infected stomachs, the organism acts to reduce gastric acidity through production of urease. In recent years, H. pylori has generally been eradicated whenever found with little thought to the consequences. H. pylori carriage appears to be negatively associated with conditions as broad as allergy, asthma, obesity and acid reflux, all conditions on the rise, suggesting that the health consequences of population-level eradication of H. pylori may be significant.1 Current consensus guidelines on H. pylori in childhood are ambiguous about eradication of the organism when identified incidentally; however, eradication is supported by UK paediatric gastroenterologists when the organism is found, including in an otherwise normal-appearing stomach.2 3 The diagnosis and management of H. pylori in children are well described in the joint consensus guideline of European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and North American Society of Paediatric Gastroenterology, Hepatology and Nutrition (summarised in box 1),3 with diagnosis having been summarised recently for Archives sister journal.4 Further discussion on H. pylori diagnosis and management therefore is out with the scope of this review. The emergence of a ‘new’ clinical atopic disease in the oesophagus, EO, around 20 years ago has not yet been fully explained.5 Data are however emerging supporting a negative association between H. pylori and EO, including in children.6 7 One challenge of linking other conditions to H. pylori is the confounder of the hygiene hypothesis as atopic
conditions have long been linked to increasing societal cleanliness, with H. pylori infection being increased in the opposite circumstance. The impact of a continued reduction in H. pylori prevalence on the health of children warrants significant consideration, particularly in the aetiological study of emerging diseases or those with changing incidence. It is unlikely however that the current decline in H. pylori prevalence can now be halted, and since there is unlikely to be uptake for deliberate inoculation of healthy people with a known carcinogen, there is likely little that can be done to address the unintended pathophysiological sequelae of H. pylori eradication.
EOSINOPHILIC OESOPHAGITIS EO is a primary oesophageal disorder characterised by an eosinophilic inflammatory infiltrate, driven by airborne or food-based allergens and resulting in oesophageal dysfunction. Symptoms vary with age of presentation, becoming more localised and specific with age.8 9 Younger children often present with vague symptoms such as feeding disorders, vomiting and abdominal pain, while the more specific symptoms of dysphagia and food impaction are more associated with teenage patients.8 The natural history is not fully understood but may lead to oesophageal stricture in untreated patients (figure 1). Affected patients are often atopic, particularly to foods, with an unexplained almost 3/4 male preponderance.10 11 Diagnosis of EO relies on oesophageal biopsy in children symptomatic of oesophageal dysfunction and so vigilance is required in identifying appropriate patients for endoscopic investigation, particularly in general or atopic paediatric practice (box 2). Confirmation of >15 eosinophils per highpowered field is the current standard diagnostic criterion.12 The oesophagus may look normal on endoscopy and, although there are no pathognomic features, some characteristic findings may be seen macroscopically such as trachealisation. Recent recommendations support taking 2–4 biopsies from the upper and lower oesophagus with important caveats being that gastroesophageal reflux disease is the main differential diagnosis, and endoscopic oesophageal pinch biopsies sample only the superficial mucosa.12 Initial confusion surrounding eosinophilic infiltration in gastroesophageal reflux disease and the early dogma that EO was non-responsive to acidsuppressant therapy have since been addressed with the recognition that a subset of patients with apparent EO are responsive to proton pump inhibitors (PPI).12 13 This is pragmatically an important point for the general paediatrician, with symptoms unresponsive to PPI acting as a good marker for tertiary gastroenterology referral (box 2). The concept of
Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
1
Copyright Article author (or their employer) 2015. Produced by BMJ Publishing Group Ltd (& RCPCH) under licence.
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Review Box 1 The diagnosis and management of Helicobacter pylori based on the European Society of Paediatric Gastroenterology, Hepatology and Nutrition/the North American Society of Paediatric Gastroenterology, Hepatology and Nutrition Guidelines (2011)3 Initial diagnosis ▸ Symptomatic children should be tested with the aim of diagnosing the cause of symptoms rather than simply identifying H. pylori. ▸ Testing those with a family history of gastric cancer or idiopathic iron deficiency anaemia should be considered. ▸ Testing in functional abdominal pain is not recommended. ▸ Upper gastrointestinal endoscopy with biopsy for histology/ rapid urease test is the recommended gold-standard for its ability to correlate carriage with associated pathology. ▸ Blood-based serology tests are not reliable for use in routine clinical practice in children. ▸ Non-invasive tests, for example, stool antigen testing, should be reserved for confirmation of eradication. Management ▸ First-line eradication regimens include triple therapy with omeprazole, amoxicillin, metronidazole; omeprazole, amoxicillin and clarithromycin; bismuth salts, amoxicillin and metronidazole or sequential therapy. ▸ Triple therapy duration should be 7–14 days. (As eradication rates are highest during the first treatment course and increased by up to 5% in 14-day courses, 14 days is the favoured option of the authors.)38 Confirmation of eradication ▸ Eradication of H. pylori should be confirmed 4–8 weeks after treatment. ▸ Patients should be off acid suppression for at least two weeks and antibiotics for at least four weeks before testing. ▸ Confirmation of eradication should be based on faecal antigen testing or urease breath test, with the former becoming the standard of practice because of ease of testing.
PPI responsiveness has since been incorporated into ESPGHAN consensus guidelines with the, perhaps confusing but pragmatic, description of PPI-responsive oesophageal eosinophilia (PPI-ROE).12 It remains unclear whether PPI-ROE and EO are distinct entities; nevertheless, the first step in the management of EO within the recent guidelines is to test for PPI responsiveness, presumably as this then becomes the mainstay therapy for this group of (∼4/10) patients. Confirmation of response should be histological, with one of the major challenges of caring for EO children being a reliance on endoscopy for objective
evaluation of disease progression, although change in symptoms can be a useful proxy in some patients. No surrogate biomarker of oesophageal eosinophilic infiltration is in current routine practice. For children not responsive to PPI treatment, there are two competing options, each with similar efficacy, namely dietary restriction and use of topical steroids. Taking these in turn, dietary therapy is most effective when a restrictive elemental diet is used (96% remission), though this is socially inconvenient and difficult to maintain in the medium to long term.14 Efficacy is reduced but similarly high (81% remission) with a six-food elimination diet excluding milk, egg, soya, wheat, nuts ( peanuts and tree nuts) and fish (including shellfish).14 About a third of children will respond to a single food exclusion, and remission rates of 77% can be achieved by milk exclusion in addition to targeted exclusion based on positive skin-prick and allergen patch testing, though the sensitivity/specificity of tests vary considerably with different foods.15 There is currently no randomised controlled trial (RCT) evidence supporting nutritional therapy in EO. Steroid intervention is however supported by specific paediatric RCTs with both fluticasone and budesonide having proven efficacy against placebo when swallowed.16 17 ‘Asthma-type’ steroids are used in order to take advantage of topical effect in the oesophagus but high first-pass metabolism and a subsequent reduction in systemic side effects. Swallowed asthma-type steroids that are extensively metabolised by first–pass metabolism (eg, beclomethasone, fluticasone) are particularly useful where aeroallergens are implicated in the development of EO. The current EO guidelines do not advocate dietary therapy over topical steroids or vice versa, but present a choice after failed response to PPI treatment.12 Systemic steroids are not recommended out with severe dysphagia, dehydration, weight loss, oesophageal strictures and failure of other treatments. Although it is recognised that stricturing can occur in EO, the natural history of this complication has not been fully described, hence the desired outcome in EO management at present remains histological remission, which is not always linked to clinical response. Again, a dependence on endoscopic reassessment is currently required in these children, at least until an adequate non-invasive surrogate marker is widely available. For the general paediatrician, an awareness of EO and its clinical manifestation and investigation will help in identifying such patients from within cohorts of other atopic disease. The requirement for endoscopy will mean paediatric gastroenterologists are likely to manage the majority of these patients in the long term at present.
COELIAC DISEASE Coeliac disease continues to remain as a major childhood healthcare problem in the UK. A recent report from Scotland showed that the incidence of coeliac disease has increased from 1.8 to 11.7/100 000 between the period of 1990 to 1994 and 2005 to 2009, respectively.18 This paper showed an actual increase in the number of children presenting with classic
Figure 1 Natural history of eosinophilic oesophagitis symptoms in childhood.
2
Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Review Box 2 When to suspect eosinophilic oesophagitis Children 10 years Dysphagia or odynophagia symptoms, particularly if gradual onset. Food bolus obstruction in the oesophagus. All children Chronic vomiting or food regurgitation. Non-specific chest or abdominal pain in atopic child. Unexplained weight loss/food avoidance, particularly in atopic child. Gastroesophageal reflux symptoms unresponsive to proton pump inhibitors therapy.
symptoms of coeliac disease and also the children diagnosed with coeliac disease by active screening. The increased incidence of coeliac disease over the last three decades has been reported in South Wales as well.19 In this Welsh study, it was noted that >50% of patients exhibited few or no symptoms of coeliac disease and that the median age of diagnosis of coeliac disease had increased. The British Society of Paediatric Gastroenterology, Hepatology and Nutrition and ESPGHAN have published guidelines recently on the diagnosis of coeliac disease in children.20 21 These guidelines allow the diagnosis of coeliac disease in symptomatic children without endoscopy and duodenal biopsy if they have significantly elevated coeliac antibody titres (ie, tissue transglutaminase >10 times upper limit of normal) on two occasions and high-risk human leucocyte antigen (HLA) genotype (HLA DR3-DQ2 or DR4-DQ8). This diagnostic approach without endoscopy and biopsy contrasts with the recently published guideline for diagnosis of coeliac disease in adults, where the recommendation is for biopsy confirmation of coeliac disease.22 It is important to highlight that children should not be started on gluten-free diet for coeliac disease without the diagnosis being confirmed by a paediatric gastroenterologist or paediatrician with gastroenterology interest. Genetics and dietary exposure of gluten are important factors in the development of coeliac disease. HLA DR3-DQ2 and DR4-DQ8 are the strongest susceptibility loci in the development of coeliac disease. However, not everyone with these HLA genotypes develop coeliac disease. The chance of developing coeliac disease in children with genetic risk depends on the gene dose effect.23 A total of 6403 children with HLA haplotype DR3-DQ2 or DR4-DQ8 were followed up prospectively from birth. The risks of coeliac disease-associated antibody positivity and coeliac disease by the age of 5 years were 11% and 3%, respectively, among children with a single DR3-DQ2 haplotype and 26% and 11%, respectively, among those with two copies (DR3-DQ2 homozygosity). These results show that the DR3-DQ2 haplotype has a gene dose effect. Strict and lifelong gluten-free diet is the treatment of coeliac disease. Gluten-free diet normalises the small bowel mucosal changes and also reduces the symptoms of coeliac disease. Gluten-free diet is also recommended for asymptomatic patients with coeliac disease. Many asymptomatic patients challenge this advice based on the practical difficulties of adhering to a restricted diet when they cannot perceive the symptomatic Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
improvement. Recent reports from Finland showed that gastrointestinal symptoms, coeliac disease-associated antibodies and mucosal changes improved in asymptomatic adults with coeliac serology positivity when randomised to gluten-free diet compared with the group randomised to gluten-containing diet.24 Only social function scores improved more in the glutencontaining diet group than in the gluten-free diet group. No study subjects considered their experience to be negative and most expected to remain on gluten-free diet. Research is progressing in the field of non-dietary treatment of coeliac disease. Recently, recombinant gluten-specific proteases have been found to be effective in adult patients with coeliac disease.25 ALV003 contains a prolyl endopeptidase from Sphingomonas capsulate in combination with another endopeptidase from germinating barley. Adults with biopsy-proven coeliac disease were randomised to receive ALV003 or placebo drug along with daily gluten challenge. Gastrointestinal symptoms secondary to gluten ingestion and mucosal injury were greater in the placebo group. There are currently no effective strategies for the prevention of coeliac disease. The Norwegian Mother and Child Cohort Study found an increased risk of coeliac disease in children introduced to gluten after 6 months.26 However, this finding is not replicated in the recently published research by Italian Society of Pediatric Gastroenterology Hepatology and Nutrition, which showed that neither breast feeding nor delayed introduction of gluten prevented the development of coeliac disease among infants at high risk.27 A total of 832 newborn infants who had a first-degree relative with coeliac disease were randomised to introduction of gluten at 6 or 12 months. The study subjects were screened for coeliac disease by serology testing at regular intervals. Even though at 2 years of age coeliac disease incidence was lower in children with delayed gluten introduction, at 5 years of age, coeliac serology positivity or overt coeliac disease was not significantly different between the two groups. A high-risk HLA genotype (HLA DR3-DQ2 or DR4-DQ8) was the most important factor in the development of coeliac disease (box 3).
INFLAMMATORY BOWEL DISEASE The diagnosis of IBD has become more commonplace during paediatric years.28 Recent studies have particularly noted a rapid rise in the number of children diagnosed with Crohn’s disease making an up-to-date knowledge of the presentation together with the initial investigation and management all the more important. Although the median age at which children are diagnosed with IBD has dropped slightly, clearly the presenting features and examination findings of IBD have not (table 1). Particular attention on examination should be paid to perioral and perianal inspection in children suspected of having Crohn’s disease, as well as measurement and plotting of growth parameters in all children. In children suspected to have IBD, after exclusion of enteric infection (including Clostridium difficile), a panel of simple blood tests (full blood count, erythrocyte sedimentation rate, C-reactive protein, liver function test) will show at least one abnormality in around 80% of children.29 In children where the diagnosis still remains uncertain, the measurement of a faecal inflammatory marker (most commonly faecal calprotectin (FC)) is helpful. Confirmation of a diagnosis of suspected IBD should then be made by a specialist in paediatric gastroenterology using upper and lower gastrointestinal endoscopy with biopsy together with small bowel imaging.30 Recently, the traditional examination of a barium follow-through to assess the small 3
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Review Box 3 Recent advances in coeliac disease
Box 4 Diagnostic use of faecal calprotectin
▸ Coeliac disease can be diagnosed in a selected group of symptomatic children without the need for endoscopy and biopsy ▸ Human leucocyte antigen DR3-DQ2 and DR4-DQ8 are the strongest susceptibility loci in the development of coeliac disease. ▸ Strict and lifelong gluten-free diet is the recommended treatment for both symptomatic and asymptomatic patients with coeliac disease. ▸ Research is progressing in the field of non-dietary treatment of coeliac disease. ▸ There are no effective preventive strategies for coeliac disease.
▸ Faecal calprotectin complements clinical review of patients with gastrointestinal symptoms and should not be used in isolation but in parallel with the clinical picture ▸ Minor elevation of faecal calprotectin above the normal range (usually reported as 250 mg/g. ▸ In healthy preschool children, faecal calprotectin is above the normal adult range. Referral for further gastrointestinal investigations or opinion should be based predominantly on symptoms as faecal calprotectin is not usually helpful in this age group. ▸ Faecal calprotectin is significantly raised at inflammatory bowel disease diagnosis in the vast majority of children, even in the presence of normal blood tests. ▸ Other conditions causing significant elevation of faecal calprotectin include enteric infection and juvenile polyps.
bowel has been replaced by small bowel MRI imaging, usually enterography.
ROLE OF FC IN THE DIAGNOSIS OF IBD FC is a neutrophil marker that can be easily and relatively inexpensively measured in serum and stool. Its great clinical utility is being able to differentiate between non-infectious diarrhoea and IBD (box 4). Studies have clearly demonstrated that the median value at paediatric IBD diagnosis is higher than that of healthy paediatric controls who have been shown conclusively not to have IBD by endoscopy and biopsy.31 In this study, a median value of 1265 mg/g was found in treatment naïve patients with IBD at diagnosis compared with controls who had a value of 65 mg/g. The exact value that signifies when a patient should have further investigation for IBD is not universally agreed, but in working practice the authors would use a value of >250 mg/g to signify the need for follow-up or further investigations.32 The reported normal range of FC is 160 genes implicated in IBD pathogenesis.33 There is no major difference between the genetics of IBD in children and adults despite the fact that children have a more extensive disease phenotype. This similarity excludes patients with very early onset disease under age 6 and especially under age 2 who have often been found to have a monogenic cause for their IBD rather than the polygenic disease of older children and adults.34 These scientific advances have not been widely translated into clinical practice in contrast to targeted pharmacogenomic studies that look to represent an area of exciting clinical application of these recent genetic advances.35 The genetic work has been paralleled and perhaps overtaken by studies examining changes in the microbiome prior to and during IBD disease course. Indeed, the largest genetic IBD study undertaken to date in IBD has placed genetic response to the gut microbiome at the core of IBD pathogenesis.36 The altered gut microbiome at IBD diagnosis with an imbalance of the microbiota compared with healthy controls is generally described by the term ‘dysbiosis’.37 Crohn’s disease is likely to result from a reduced bacterial diversity within the gut microbiome but an increase in the total number of bacteria compared with healthy controls. Scientific evidence exists for specific species in the aetiology of these changes, for example, pathogenic strains of Escherichia coli, but in truth the key species driving these changes vary between study populations and Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Review methodologies so the search for the ‘gatekeeper’ continues. There are active research programmes looking at how these bacterial populations can be changed clinically using, for example, exclusive enteral nutrition in Crohn’s disease and faecal transplantation in ulcerative colitis. Microbial therapeutics looks likely to become the next revolution in IBD therapy. The management of IBD has been extensively updated recently with several joint publications from ESPGHAN and European Crohn’s and Colitis Organisation in the past few years and hence not covered in this review. Acknowledgements The Yorkhill IBD team is generously supported by the Catherine McEwan Foundation and the Yorkhill IBD fund. RKR is supported by an NHS Research Scotland career fellowship award and MRC extension grant for PICTS (G0800675). Contributors All the authors have contributed equally to the manuscript drafting, review and revision. All authors approved the final manuscript as submitted. Competing interests RH has received speaker’s fees and/or travel support from MSD Immunology, Dr Falk and SHS Nutricia. RKR has received speaker’s fees, travel support and/or participated in medical board meetings with MSD Immunology, Abbvie, Dr Falk, Nestle, Janssen, Takeda and Napp. RM has received speaker’s fees, educational support and research grants from Abbvie, Dr Falk, MSD Immunology, Nestle and Tilotts Pharma. Provenance and peer review Commissioned; externally peer reviewed.
15
16
17
18 19 20
21
22
23 24
25
REFERENCES 1 2 3
4 5 6 7
8
9 10 11
12 13
14
Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009;119:2475–87. Goddard M, Lloyd C, Beattie RM, et al. Paediatric Helicobacter pylori practice in the United Kingdom: a BSPGHAN survey. J Pediatr Gastroenterol Nutr 2012;55:339. Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011;53:230–43. Crowley E, Bourke B, Hussey S. How to use Helicobacter pylori testing in paediatric practice. Arch Dis Child Educ Pract Ed 2013;98:18–25. Attwood SE, Smyrk TC, DeMeester TR, et al. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 1993;38:109–16. Elitsur Y, Alrazzak BA, Preston D, et al. Does Helicobacter pylori protect against eosinophilic esophagitis in children? Helicobacter 2014;19:367–71. Dellon ES, Peery AF, Shaheen NJ, et al. Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology 2011;141:1586–92. Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009;48:30–6. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004;351:940–1. van Rhijn BD, Verheij J, Smout AJ, et al. Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. Neurogastroenterol Motil 2013;25:47–52. Dalby K, Nielsen RG, Kruse-Andersen S, et al. Eosinophilic oesophagitis in infants and children in the region of southern Denmark: a prospective study of prevalence and clinical presentation. J Pediatr Gastroenterol Nutr 2010;51:280–2. Papadopoulou A, Koletzko S, Heuschkel R, et al. Management guidelines of eosinophilic esophagitis in childhood. J Pediatr Gastroenterol Nutr 2014;58:107–18. Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 2009;154:96–100. Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2012;129:1570–8.
Hansen R, et al. Arch Dis Child 2015;0:1–5. doi:10.1136/archdischild-2014-307089
26 27 28 29
30
31
32
33 34 35
36 37
38
Spergel JM, Brown-Whitehorn TF, Cianferoni A, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol 2012;130:461–7. Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139:418–29. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:1381–91. White LE, Merrick VM, Bannerman E, et al. The rising incidence of celiac disease in Scotland. Pediatrics 2013;132:e924–31. Whyte LA, Jenkins HR. The epidemiology of coeliac disease in South Wales: a 28-year perspective. Arch Dis Child 2013;98:405–7. Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease. J Pediatr Gastroenterol Nutr 2012;54:136–60. Murch S, Jenkins H, Auth M, et al. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children. Arch Dis Child 2013;98:806–11. Ludvigsson JF, Bai JC, Biagi F, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut 2014;63:1210–28. Liu E, Lee HS, Aronsson CA, et al. Risk of pediatric celiac disease according to HLA haplotype and country. N Engl J Med 2014;371:42–9. Kurppa K, Paavola A, Collin P, et al. Benefits of a gluten-free diet for asymptomatic patients with serologic markers of celiac disease. Gastroenterology 2014;147:610–17. Lahdeaho ML, Kaukinen K, Laurila K, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 2014;146:1649–58. Stordal K, White RA, Eggesbo M. Early feeding and risk of Celiac disease in a prospective birth cohort. Pediatrics 2013;132:e1202–9. Lionetti E, Castellaneta S, Francavilla R, et al. Introduction of gluten, HLA status, and the risk of celiac disease in children. N Engl J Med 2014;371:1295–303. Henderson P, Hansen R, Cameron FL, et al. The rising incidence of paediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis 2012;18:999–1005. Quail MA, Russell RK, Van Limbergen JE, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis 2009;15:756–9. Levine A, Koletzko S, Turner D, et al. The ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents. J Pediatr Gastroenterol Nutr 2013;58:795–806. Henderson P, Casey A, Lawrence SJ, et al. The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease. Am J Gastroenterol 2012;107:941–9. Henderson P, Anderson NH, Wilson DC. The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2014;109:637–45. Van LJ, Radford-Smith G, Satsangi J. Advances in IBD genetics. Nat Rev Gastroentero Hepatol 2014;11:372–85. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut 2013;62:1795–805. Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014;46:1131–4. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119–24. Hold GL, Smith M, Grange C, et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 2014;20:1192–210. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646–64.
5
Downloaded from http://adc.bmj.com/ on March 26, 2015 - Published by group.bmj.com
Recent advances in paediatric gastroenterology Richard Hansen, Richard K Russell and Rafeeq Muhammed Arch Dis Child published online February 20, 2015
Updated information and services can be found at: http://adc.bmj.com/content/early/2015/02/20/archdischild-2014-30708 9
These include:
References
This article cites 38 articles, 8 of which you can access for free at: http://adc.bmj.com/content/early/2015/02/20/archdischild-2014-30708 9#BIBL
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.
Topic Collections
Articles on similar topics can be found in the following collections Metabolic disorders (673)
Notes
To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions To order reprints go to: http://journals.bmj.com/cgi/reprintform To subscribe to BMJ go to: http://group.bmj.com/subscribe/
